Raymond W Lee, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 6 carriers
- Office
- 1
Offices
1 location
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
28 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lee’s office at (408) 923-3388 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G44983 · Current
Licensed to practise in California · since 1981 · expires 2027-01-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
5 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 350 |
| Closing the Referral Loop: Receipt of Specialist ReportAs Medicare defines this measure | 100% | 98 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 1,280 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 100% | 1,060 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 550 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$33,768
Medicare paid this office $33,768 for 161 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 91 | $16,633 | $96 |
| Short return visit (20+ min) | 87 | $7,770 | $63 |
| New patient visit (60+ min) | 18 | $3,066 | $170 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,504 | $100 |
| Insertion of needle into vein for collection of blood sample | 12 | $67 | $5 |
Who their Medicare patients are
161 Original Medicare patients in 2024. Average age 78 · Women 62% · Also on Medicaid 65% · Health risk score 2.28. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 55% · Chronic kidney disease 45% · Cancer 39% · Coronary heart disease 27% · Heart failure 20% · COPD 17% · Atrial fibrillation 15% · Depression 12% · Dementia 12% · Stroke 9%.
The office billed $79,651, Medicare allowed $48,793 and paid $33,768; for 1,309 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 161 | 1,309 | 78 | 2.28 | $79,651 | $33,768 |
| 2023 | 151 | 2,682 | 77 | 2.08 | $80,380 | $37,420 |
| 2022 | 205 | 17,209 | 76 | 1.91 | $149,036 | $65,842 |
| 2021 | 297 | 64,400 | 76 | 1.95 | $385,391 | $184,405 |
| 2020 | 306 | 62,183 | 76 | 2.21 | $409,095 | $196,417 |
| 2019 | 400 | 49,771 | 75 | 2.05 | $409,821 | $210,073 |
| 2018 | 398 | 39,878 | 75 | 2.14 | $328,650 | $169,949 |
| 2017 | 504 | 61,260 | 75 | 2.06 | $483,038 | $242,556 |
| 2016 | 490 | 29,418 | 75 | 2.11 | $352,605 | $179,448 |
| 2015 | 527 | 39,345 | 75 | 2.23 | $470,843 | $242,146 |
| 2014 | 577 | 35,462 | 75 | 2.08 | $573,229 | $300,999 |
| 2013 | 700 | 33,187 | 75 | 1.95 | $766,820 | $413,179 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit (20+ min) | 101 | $12,319 | $73 |
| Return visit (30+ min) | 64 | $10,520 | $110 |
| New patient visit (60+ min) | 15 | $2,631 | $175 |
| Insertion of needle into vein for collection of blood sample | 17 | $103 | $5 |
2022: 10 services
| Short return visit (20+ min) | 143 | $17,388 | $73 |
| Return visit (30+ min) | 59 | $8,708 | $110 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $8,665 | $135 |
| New patient visit (60+ min) | 11 | $2,028 | $184 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,851 | $116 |
| Injection of additional new drug or substance into vein | 18 | $1,734 | $15 |
| New patient visit (45+ min) | 11 | $1,426 | $130 |
| Infusion, normal saline solution, 250 cc | 22 | $116 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $112 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $45 | None |
2021: 12 services
| Short return visit (20+ min) | 221 | $36,469 | $80 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $14,100 | $152 |
| Return visit (30+ min) | 77 | $12,833 | $115 |
| Injection of additional new drug or substance into vein | 28 | $7,070 | $17 |
| New patient visit (60+ min) | 20 | $4,120 | $206 |
| New patient visit (45+ min) | 27 | $3,875 | $144 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,529 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,319 | $166 |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $476 | None |
| Infusion, normal saline solution, 250 cc | 31 | $322 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $65 | None |
| Insertion of needle into vein for collection of blood sample | 15 | $51 | $3 |
2020: 25 services
| Short return visit (20+ min) | 217 | $28,969 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $28,317 | $149 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 19 | $21,557 | $171 |
| Return visit (30+ min) | 83 | $12,228 | $99 |
| Administration of additional new drug or substance into vein using push technique | 24 | $9,221 | $58 |
| Injection of additional new drug or substance into vein | 38 | $6,784 | $17 |
| New patient visit (60+ min) | 25 | $4,894 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,073 | $185 |
| Irrigation of implanted venous access drug delivery device | 20 | $2,651 | $29 |
| Administration of chemotherapy into vein, each additional hour | 17 | $2,568 | $31 |
| New patient visit (45+ min) | 16 | $2,369 | $148 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $2,008 | $126 |
| Injection, oxaliplatin, 0.5 mg | 12 | $1,984 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,656 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 16 | $1,615 | $22 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,571 | $92 |
| Injection, fluorouracil, 500 mg | 19 | $1,261 | None |
| Short return visit | 11 | $606 | $40 |
| Injection, ondansetron hydrochloride, per 1 mg | 39 | $498 | None |
| Infusion, normal saline solution, 250 cc | 43 | $413 | None |
| Injection, leucovorin calcium, per 50 mg | 17 | $403 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $203 | $16 |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $113 | None |
| Insertion of needle into vein for collection of blood sample | 26 | $95 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 26 | $16 | None |
2019: 25 services
| Short return visit (20+ min) | 305 | $40,327 | $66 |
| Administration of chemotherapy into vein, 1 hour or less | 29 | $33,747 | $145 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 17 | $26,984 | $169 |
| Return visit (30+ min) | 112 | $17,318 | $97 |
| Injection of additional new drug or substance into vein | 38 | $9,287 | $17 |
| Administration of additional new drug or substance into vein using push technique | 18 | $9,001 | $59 |
| New patient visit (60+ min) | 31 | $5,923 | $191 |
| Administration of chemotherapy into vein, each additional hour | 19 | $4,660 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,342 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,164 | $65 |
| New patient visit (45+ min) | 22 | $3,135 | $142 |
| Injection, oxaliplatin, 0.5 mg | 13 | $2,680 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 16 | $2,540 | $21 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $2,507 | $90 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,439 | $122 |
| Long return visit (40+ min) | 12 | $1,656 | $127 |
| Injection, fluorouracil, 500 mg | 18 | $1,649 | None |
| Short return visit | 18 | $1,052 | $44 |
| Injection, leucovorin calcium, per 50 mg | 18 | $758 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 38 | $563 | None |
| Infusion, normal saline solution, 250 cc | 37 | $366 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 12 | $198 | $15 |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $129 | None |
| Insertion of needle into vein for collection of blood sample | 24 | $94 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 30 | $19 | None |
2018: 20 services
| Short return visit (20+ min) | 305 | $42,596 | $65 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $28,174 | $148 |
| Return visit (30+ min) | 67 | $10,566 | $90 |
| Administration of additional new drug or substance into vein using push technique | 19 | $9,490 | $60 |
| Injection of additional new drug or substance into vein | 30 | $8,211 | $18 |
| New patient visit (60+ min) | 35 | $6,588 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,314 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,661 | $65 |
| New patient visit (45+ min) | 18 | $2,613 | $145 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $2,066 | $90 |
| Injection, paclitaxel, 1 mg | 15 | $1,184 | None |
| Injection, carboplatin, 50 mg | 11 | $789 | None |
| Injection, fluorouracil, 500 mg | 11 | $769 | None |
| Short return visit | 17 | $725 | $43 |
| Injection, ondansetron hydrochloride, per 1 mg | 32 | $350 | None |
| Infusion, normal saline solution, 250 cc | 33 | $316 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $181 | $15 |
| Insertion of needle into vein for collection of blood sample | 25 | $97 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 27 | $88 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 29 | $18 | None |
2017: 30 services
| Short return visit (20+ min) | 362 | $49,048 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 33 | $28,905 | $137 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 15 | $13,953 | $157 |
| New patient visit (60+ min) | 70 | $12,766 | $182 |
| Administration of additional new drug or substance into vein using push technique | 29 | $11,985 | $62 |
| New patient visit (45+ min) | 78 | $10,683 | $137 |
| Return visit (30+ min) | 78 | $9,613 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,089 | $176 |
| Injection of additional new drug or substance into vein | 28 | $7,832 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $6,410 | $63 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 23 | $6,096 | $29 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 47 | $5,047 | $87 |
| Injection, oxaliplatin, 0.5 mg | 13 | $4,619 | None |
| Biopsy of bone marrow | 16 | $2,618 | $164 |
| Administration of chemotherapy into vein, each additional hour | 15 | $2,457 | $28 |
| Injection, zoledronic acid, 1 mg | 12 | $1,817 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,783 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,539 | $118 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $1,512 | $20 |
| Short return visit | 21 | $1,144 | $39 |
| Injection, leucovorin calcium, per 50 mg | 14 | $1,088 | None |
| Injection, fluorouracil, 500 mg | 15 | $1,087 | None |
| Injection, paclitaxel, 1 mg | 11 | $946 | None |
| Injection, carboplatin, 50 mg | 14 | $904 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 41 | $415 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $175 | $13 |
| Insertion of needle into vein for collection of blood sample | 37 | $165 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 36 | $131 | None |
| Infusion, normal saline solution, 250 cc | 20 | $119 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $25 | None |
2016: 21 services
| Short return visit (20+ min) | 319 | $41,897 | $62 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | $19,642 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $19,043 | $173 |
| Administration of additional new drug or substance into vein using push technique | 29 | $11,802 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $10,172 | $29 |
| New patient visit (60+ min) | 53 | $9,491 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 81 | $9,077 | $62 |
| Return visit (30+ min) | 62 | $7,639 | $86 |
| New patient visit (45+ min) | 49 | $6,888 | $141 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 58 | $5,912 | $86 |
| Administration of chemotherapy into vein using push technique | 13 | $5,904 | $109 |
| Biopsy of bone marrow | 12 | $2,093 | $161 |
| Short return visit | 26 | $1,158 | $40 |
| Injection, carboplatin, 50 mg | 17 | $881 | None |
| Injection, fluorouracil, 500 mg | 12 | $589 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $354 | $15 |
| Injection, ondansetron hydrochloride, per 1 mg | 36 | $330 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 16 | $205 | $12 |
| Insertion of needle into vein for collection of blood sample | 21 | $109 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 32 | $85 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $20 | None |
2015: 21 services
| Short return visit (20+ min) | 342 | $42,445 | $66 |
| Administration of chemotherapy into vein, 1 hour or less | 28 | $27,595 | $140 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $20,808 | $181 |
| New patient visit (60+ min) | 87 | $16,037 | $184 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $15,577 | $31 |
| Administration of additional new drug or substance into vein using push technique | 30 | $13,183 | $64 |
| Administration of chemotherapy into vein using push technique | 18 | $12,757 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $9,708 | $65 |
| Return visit (30+ min) | 66 | $9,348 | $94 |
| New patient visit (45+ min) | 60 | $9,024 | $150 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 49 | $5,564 | $90 |
| Injection, zoledronic acid, 1 mg | 11 | $2,973 | None |
| Biopsy of bone marrow | 14 | $2,346 | $168 |
| Injection, carboplatin, 50 mg | 24 | $1,767 | None |
| Injection, paclitaxel, 1 mg | 14 | $1,428 | None |
| Short return visit | 24 | $1,241 | $39 |
| Injection, ondansetron hydrochloride, per 1 mg | 39 | $337 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $213 | $16 |
| Insertion of needle into vein for collection of blood sample | 33 | $147 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $96 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $20 | None |
2014: 24 services
| Short return visit (20+ min) | 379 | $49,304 | $65 |
| Administration of chemotherapy into vein, 1 hour or less | 27 | $29,961 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 119 | $21,477 | $179 |
| New patient visit (60+ min) | 88 | $16,530 | $188 |
| Administration of additional new drug or substance into vein using push technique | 27 | $15,067 | $62 |
| Administration of chemotherapy into vein using push technique | 17 | $14,843 | $111 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $13,535 | $30 |
| Injection, zoledronic acid, 1 mg | 15 | $13,464 | None |
| Return visit (30+ min) | 85 | $11,088 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 80 | $10,184 | $64 |
| New patient visit (45+ min) | 60 | $8,898 | $148 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 49 | $5,445 | $89 |
| Biopsy of bone marrow | 17 | $2,565 | $151 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,461 | $122 |
| Short return visit | 28 | $1,370 | $42 |
| Destruction of precancer skin growth, 1 growth | 12 | $945 | $63 |
| Injection, leucovorin calcium, per 50 mg | 12 | $735 | None |
| Injection, carboplatin, 50 mg | 13 | $556 | None |
| Injection, fluorouracil, 500 mg | 14 | $452 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 38 | $426 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 16 | $320 | $16 |
| Insertion of needle into vein for collection of blood sample | 51 | $231 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $60 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $10 | None |
2013: 32 services
| Short return visit (20+ min) | 482 | $61,402 | $66 |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $43,638 | $147 |
| Fecal microbiota, live - jslm, 1 ml | 16 | $35,370 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 138 | $24,162 | $175 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 60 | $22,077 | $32 |
| Administration of chemotherapy into vein using push technique | 35 | $20,887 | $114 |
| Administration of additional new drug or substance into vein using push technique | 43 | $19,907 | $64 |
| New patient visit (60+ min) | 101 | $18,724 | $185 |
| New patient visit (45+ min) | 107 | $15,709 | $147 |
| Zoldedronic acid 1mg | 12 | $13,833 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 100 | $10,933 | $62 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 76 | $7,965 | $87 |
| Return visit (30+ min) | 52 | $6,993 | $92 |
| Injection of drug or substance under skin or into muscle | 18 | $6,457 | $25 |
| Drawing of blood for a medical problem | 11 | $3,572 | $102 |
| Biopsy of bone marrow | 20 | $3,298 | $165 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $2,857 | None |
| Short return visit | 60 | $2,700 | $41 |
| Injection, paclitaxel, 30 mg | 16 | $1,252 | None |
| Injection, leucovorin calcium, per 50 mg | 15 | $1,116 | None |
| Destruction of precancer skin growth, 1 growth | 15 | $1,078 | $67 |
| Infusion into a vein for hydration, each additional hour | 19 | $1,053 | $15 |
| Injection, carboplatin, 50 mg | 21 | $1,035 | None |
| New patient visit (30+ min) | 11 | $966 | $88 |
| Injection, ondansetron hydrochloride, per 1 mg | 61 | $918 | None |
| Injection, fluorouracil, 500 mg | 17 | $499 | None |
| Insertion of needle into vein for collection of blood sample | 64 | $284 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 15 | $248 | $17 |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $143 | None |
| Injection, calcium gluconate (fresenius kabi), per 10 ml | 18 | $33 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $19 | None |
| Injection, magnesium sulfate, per 500 mg | 16 | $6 | None |
Medicaid work
$1,540 in 2024
Medicaid paid $1,540 for 495 billed services this clinician did in 2024, up to 43 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 187 | $873 |
| Short return visit (20+ min) | 308 | $667 |
| 2024 | 495 | 2 | 43 | $1,540 |
| 2023 | 579 | 2 | 53 | $1,447 |
| 2022 | 659 | 6 | 48 | $382 |
| 2021 | 473 | 2 | 46 | $284 |
| 2020 | 521 | 2 | 33 | $363 |
| 2019 | 418 | 1 | 41 | $0 |
| 2018 | 315 | 1 | 53 | $0 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 551 | $1,317 |
| Return visit (30+ min) | 28 | $129 |
2022
| Injection, ondansetron hydrochloride, per 1 mg | 35 | $152 |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $115 |
| Short return visit (20+ min) | 449 | $114 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 32 | $0 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 31 | $0 |
| Infusion, normal saline solution, 250 cc | 81 | $0 |
2021
| Short return visit (20+ min) | 448 | $227 |
| Injection, ondansetron hydrochloride, per 1 mg | 25 | $57 |
2020
| Short return visit (20+ min) | 490 | $363 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 31 | $0 |
2019
| Short return visit (20+ min) | 418 | $0 |
2018
| Short return visit (20+ min) | 315 | $0 |
Drugs they prescribed that Part D paid
$2,369,733
Pharmacies billed $2,369,733 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (13 of 673) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
482 generic and 191 brand-name prescriptions · $2,369,733 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 57 | $688,703 | $12,083 |
| Tagrisso | 30 | $451,391 | $15,046 |
| Sprycel | 14 | $234,058 | $16,718 |
| Revlimid | 11 | $133,966 | $12,179 |
| Lenalidomide | 13 | $103,952 | $7,996 |
See all 20 drugs
| Jakafi | 57 | $688,703 | $12,083 |
| Tagrisso | 30 | $451,391 | $15,046 |
| Sprycel | 14 | $234,058 | $16,718 |
| Revlimid | 11 | $133,966 | $12,179 |
| Lenalidomide | 13 | $103,952 | $7,996 |
| Imatinib Mesylate | 28 | $36,904 | $1,318 |
| Xarelto | 15 | $20,492 | $1,366 |
| Danazol | 13 | $2,945 | $227 |
| Raloxifene | 24 | $1,020 | $43 |
| Anastrozole | 38 | $810 | $21 |
| Hydroxyurea | 41 | $709 | $17 |
| Ondansetron Odt | 27 | $498 | $18 |
| Tamoxifen Citrate | 18 | $425 | $24 |
| Mirtazapine | 26 | $423 | $16 |
| Dexamethasone | 22 | $297 | $14 |
| Montelukast | 23 | $255 | $11 |
| Famotidine | 14 | $164 | $12 |
| Allopurinol | 11 | $121 | $11 |
| Prednisone | 16 | $62 | $4 |
| Tramadol | 13 | $61 | $5 |
Year by year
| 2024 | 673 | 169 | 2% (13) | 28% | $2,369,733 |
| 2023 | 514 | 151 | 3% (17) | 36% | $2,231,810 |
| 2022 | 1,064 | 260 | 2% (17) | 32% | $3,874,839 |
| 2021 | 1,295 | 290 | 3% (36) | 22% | $2,337,695 |
| 2020 | 1,719 | 275 | 2% (36) | 23% | $3,137,668 |
| 2019 | 2,252 | 333 | 1% (32) | 17% | $3,645,234 |
| 2018 | 2,159 | 313 | 1% (25) | None | $2,273,297 |
| 2017 | 2,722 | 352 | 2% (51) | None | $2,508,124 |
| 2016 | 2,568 | 321 | 3% (78) | None | $1,840,904 |
| 2015 | 2,112 | 276 | 4% (83) | 23% | $1,537,023 |
| 2014 | 2,026 | 249 | 3% (63) | 23% | $1,429,721 |
| 2013 | 2,383 | 294 | 4% (84) | 25% | $1,199,023 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Tagrisso | 35 | $539,997 | $15,428 |
| Jakafi | 34 | $375,788 | $11,053 |
| Sprycel | 20 | $251,966 | $12,598 |
| Revlimid | 11 | $169,930 | $15,448 |
| Promacta | 16 | $169,287 | $10,580 |
| Doptelet | 11 | $48,937 | $4,449 |
| Imatinib Mesylate | 18 | $35,555 | $1,975 |
| Raloxifene | 14 | $1,966 | $140 |
| Ondansetron Odt | 19 | $1,357 | $71 |
| Hydroxyurea | 28 | $901 | $32 |
| Anastrozole | 19 | $877 | $46 |
| Letrozole | 11 | $487 | $44 |
| Montelukast | 19 | $316 | $17 |
| Famotidine | 12 | $176 | $15 |
| Tramadol | 14 | $145 | $10 |
2022: 27 drugs
| Tagrisso | 48 | $817,749 | $17,036 |
| Revlimid | 40 | $667,244 | $16,681 |
| Jakafi | 48 | $558,007 | $11,625 |
| Ibrance | 16 | $247,364 | $15,460 |
| Xtandi | 17 | $220,109 | $12,948 |
| Sprycel | 16 | $155,624 | $9,727 |
| Promacta | 16 | $146,630 | $9,164 |
| Imatinib Mesylate | 34 | $52,122 | $1,533 |
| Sunitinib Malate | 12 | $51,221 | $4,268 |
| Everolimus | 15 | $38,277 | $2,552 |
| Xarelto | 20 | $19,941 | $997 |
| Eliquis | 12 | $9,174 | $764 |
| Deferasirox | 14 | $8,879 | $634 |
| Danazol | 38 | $6,374 | $168 |
| Raloxifene | 28 | $3,592 | $128 |
| Anastrozole | 78 | $2,425 | $31 |
| Tamoxifen Citrate | 29 | $1,779 | $61 |
| Exemestane | 12 | $1,585 | $132 |
| Montelukast | 52 | $1,546 | $30 |
| Ondansetron Odt | 48 | $1,231 | $26 |
| Hydroxyurea | 53 | $1,224 | $23 |
| Mirtazapine | 29 | $749 | $26 |
| Famotidine | 41 | $419 | $10 |
| Dexamethasone | 19 | $319 | $17 |
| Allopurinol | 11 | $208 | $19 |
| Prednisone | 25 | $155 | $6 |
| Tramadol | 14 | $90 | $6 |
2021: 29 drugs
| Revlimid | 38 | $609,349 | $16,035 |
| Jakafi | 38 | $393,778 | $10,363 |
| Tagrisso | 17 | $274,035 | $16,120 |
| Sprycel | 12 | $163,213 | $13,601 |
| Promacta | 12 | $122,265 | $10,189 |
| Imatinib Mesylate | 58 | $66,773 | $1,151 |
| Tasigna | 12 | $52,009 | $4,334 |
| Xarelto | 44 | $26,989 | $613 |
| Eliquis | 25 | $15,416 | $617 |
| Danazol | 69 | $9,975 | $145 |
| Raloxifene | 31 | $2,974 | $96 |
| Exemestane | 19 | $2,825 | $149 |
| Anastrozole | 109 | $2,572 | $24 |
| Hydroxyurea | 101 | $2,069 | $20 |
| Tamoxifen Citrate | 56 | $1,882 | $34 |
| Ondansetron Odt | 32 | $799 | $25 |
| Tenofovir Disoproxil | 18 | $628 | $35 |
| Montelukast | 50 | $603 | $12 |
| Dexamethasone | 24 | $531 | $22 |
| Famotidine | 50 | $414 | $8 |
| Mirtazapine | 24 | $371 | $15 |
| Letrozole | 12 | $337 | $28 |
| Allopurinol | 31 | $334 | $11 |
| Azathioprine | 14 | $295 | $21 |
| Tramadol | 21 | $241 | $11 |
| Prednisone | 26 | $129 | $5 |
| Amlodipine Besylate | 13 | $102 | $8 |
| Gabapentin | 11 | $87 | $8 |
| Folic Acid | 11 | $34 | $3 |
2020: 34 drugs
| Jakafi | 56 | $770,226 | $13,754 |
| Revlimid | 30 | $499,804 | $16,660 |
| Tagrisso | 24 | $376,350 | $15,681 |
| Pomalyst | 14 | $248,970 | $17,784 |
| Zytiga | 16 | $181,181 | $11,324 |
| Doptelet | 17 | $153,963 | $9,057 |
| Afinitor | 12 | $130,031 | $10,836 |
| Xtandi | 12 | $119,028 | $9,919 |
| Imatinib Mesylate | 48 | $76,537 | $1,595 |
| Xarelto | 70 | $35,781 | $511 |
| Eliquis | 34 | $17,153 | $505 |
| Danazol | 68 | $11,135 | $164 |
| Exemestane | 18 | $5,412 | $301 |
| Raloxifene | 53 | $4,005 | $76 |
| Tamoxifen Citrate | 120 | $2,736 | $23 |
| Tenofovir Disoproxil | 22 | $2,561 | $116 |
| Hydroxyurea | 125 | $2,314 | $19 |
| Anastrozole | 162 | $2,041 | $13 |
| Mirtazapine | 38 | $1,030 | $27 |
| Ondansetron Odt | 34 | $668 | $20 |
| Dexamethasone | 54 | $633 | $12 |
| Synthroid | 15 | $629 | $42 |
| Montelukast | 91 | $539 | $6 |
| Azathioprine | 17 | $421 | $25 |
| Levothyroxine | 21 | $373 | $18 |
| Famotidine | 80 | $347 | $4 |
| Allopurinol | 51 | $323 | $6 |
| Prednisone | 36 | $220 | $6 |
| Gabapentin | 19 | $133 | $7 |
| Ondansetron | 12 | $132 | $11 |
| Tramadol | 24 | $117 | $5 |
| Alendronate | 15 | $88 | $6 |
| Amlodipine Besylate | 14 | $83 | $6 |
| Sulfamethoxazole-Trimethoprim | 11 | $41 | $4 |
2019: 46 drugs
| Revlimid | 47 | $694,449 | $14,776 |
| Jakafi | 45 | $580,172 | $12,893 |
| Tagrisso | 18 | $271,962 | $15,109 |
| Nexavar | 19 | $233,351 | $12,282 |
| Ibrance | 20 | $232,158 | $11,608 |
| Pomalyst | 12 | $202,511 | $16,876 |
| Ninlaro | 18 | $185,084 | $10,282 |
| Imatinib Mesylate | 70 | $145,996 | $2,086 |
| Zytiga | 13 | $141,378 | $10,875 |
| Gilotrif | 15 | $122,772 | $8,185 |
| Xarelto | 57 | $31,176 | $547 |
| Danazol | 81 | $15,782 | $195 |
| Anagrelide | 22 | $13,564 | $617 |
| Eliquis | 22 | $11,503 | $523 |
| Raloxifene | 100 | $11,416 | $114 |
| Exemestane | 29 | $8,388 | $289 |
| Tamoxifen Citrate | 136 | $4,022 | $30 |
| Anastrozole | 277 | $3,531 | $13 |
| Hydroxyurea | 147 | $3,314 | $23 |
| Tenofovir Disoproxil | 18 | $1,914 | $106 |
| Cyclosporine Modified | 19 | $1,658 | $87 |
| Dexamethasone | 76 | $1,161 | $15 |
| Mirtazapine | 52 | $1,152 | $22 |
| Montelukast | 108 | $949 | $9 |
| Letrozole | 49 | $822 | $17 |
| Allopurinol | 79 | $764 | $10 |
| Leucovorin | 16 | $691 | $43 |
| Ondansetron Odt | 33 | $543 | $16 |
| Famotidine | 100 | $447 | $4 |
| Levetiracetam | 13 | $410 | $32 |
| Atorvastatin | 13 | $326 | $25 |
| Prednisone | 49 | $307 | $6 |
| Potassium Chloride | 18 | $299 | $17 |
| Venlafaxine Hcl Er | 12 | $236 | $20 |
| Ondansetron | 17 | $203 | $12 |
| Levothyroxine | 11 | $168 | $15 |
| Alendronate | 26 | $168 | $6 |
| Gabapentin | 19 | $168 | $9 |
| Tramadol | 21 | $165 | $8 |
| Acyclovir | 19 | $157 | $8 |
| Pramipexole Dihydrochloride | 13 | $127 | $10 |
| Omeprazole | 11 | $102 | $9 |
| Meloxicam | 15 | $102 | $7 |
| Paroxetine | 11 | $84 | $8 |
| Amlodipine Besylate | 11 | $83 | $8 |
| Warfarin | 12 | $80 | $7 |
2018: 40 drugs
| Revlimid | 31 | $385,965 | $12,450 |
| Imatinib Mesylate | 57 | $253,851 | $4,454 |
| Jakafi | 23 | $217,791 | $9,469 |
| Ibrance | 16 | $180,236 | $11,265 |
| Gilotrif | 15 | $132,058 | $8,804 |
| Nexavar | 15 | $127,070 | $8,471 |
| Iressa | 20 | $125,990 | $6,299 |
| Ninlaro | 12 | $118,391 | $9,866 |
| Procrit | 12 | $36,021 | $3,002 |
| Danazol | 102 | $24,290 | $238 |
| Xarelto | 43 | $21,776 | $506 |
| Raloxifene | 134 | $13,006 | $97 |
| Tenofovir Disoproxil | 14 | $11,518 | $823 |
| Januvia | 12 | $7,027 | $586 |
| Exemestane | 19 | $4,723 | $249 |
| Tamoxifen Citrate | 149 | $4,421 | $30 |
| Hydroxyurea | 184 | $4,317 | $23 |
| Anastrozole | 279 | $4,024 | $14 |
| Uloric | 16 | $3,175 | $198 |
| Mirtazapine | 48 | $2,009 | $42 |
| Ondansetron Odt | 45 | $1,322 | $29 |
| Anagrelide | 11 | $1,120 | $102 |
| Dexamethasone | 77 | $911 | $12 |
| Allopurinol | 79 | $732 | $9 |
| Leucovorin | 18 | $546 | $30 |
| Letrozole | 46 | $469 | $10 |
| Montelukast | 53 | $443 | $8 |
| Levetiracetam | 13 | $297 | $23 |
| Atorvastatin | 14 | $285 | $20 |
| Gabapentin | 42 | $266 | $6 |
| Alendronate | 37 | $253 | $7 |
| Acyclovir | 35 | $215 | $6 |
| Paroxetine | 26 | $214 | $8 |
| Tramadol | 13 | $195 | $15 |
| Prednisone | 33 | $177 | $5 |
| Famotidine | 37 | $174 | $5 |
| Omeprazole | 14 | $138 | $10 |
| Meloxicam | 26 | $128 | $5 |
| Hydrocortisone | 13 | $116 | $9 |
| Amlodipine Besylate | 11 | $67 | $6 |
2017: 50 drugs
| Revlimid | 70 | $802,914 | $11,470 |
| Imatinib Mesylate | 47 | $260,497 | $5,542 |
| Nexavar | 22 | $243,697 | $11,077 |
| Zytiga | 14 | $130,695 | $9,335 |
| Ibrance | 11 | $122,582 | $11,144 |
| Xtandi | 11 | $117,592 | $10,690 |
| Gleevec | 15 | $116,398 | $7,760 |
| Votrient | 12 | $76,052 | $6,338 |
| Iressa | 14 | $75,043 | $5,360 |
| Neupogen | 24 | $56,515 | $2,355 |
| Viread | 41 | $44,863 | $1,094 |
| Danazol | 127 | $41,464 | $326 |
| Procrit | 15 | $27,800 | $1,853 |
| Entecavir | 31 | $22,092 | $713 |
| Xarelto | 49 | $18,807 | $384 |
| Raloxifene | 135 | $15,104 | $112 |
| Exemestane | 30 | $11,571 | $386 |
| Hydroxyurea | 183 | $4,793 | $26 |
| Tamoxifen Citrate | 171 | $4,778 | $28 |
| Januvia | 12 | $4,680 | $390 |
| Anastrozole | 313 | $3,523 | $11 |
| Pilocarpine | 19 | $2,153 | $113 |
| Ondansetron Odt | 54 | $1,435 | $27 |
| Dexamethasone | 115 | $1,089 | $9 |
| Allopurinol | 73 | $902 | $12 |
| Letrozole | 58 | $668 | $12 |
| Prednisone | 98 | $586 | $6 |
| Anagrelide | 11 | $557 | $51 |
| Levothyroxine | 19 | $482 | $25 |
| Alendronate | 73 | $438 | $6 |
| Montelukast | 55 | $431 | $8 |
| Fluconazole | 11 | $400 | $36 |
| Potassium Chloride | 22 | $374 | $17 |
| Paroxetine | 52 | $374 | $7 |
| Atorvastatin | 14 | $341 | $24 |
| Leucovorin | 12 | $335 | $28 |
| Acyclovir | 46 | $306 | $7 |
| Famotidine | 51 | $282 | $6 |
| Spironolactone | 16 | $218 | $14 |
| Meloxicam | 46 | $177 | $4 |
| Tramadol | 27 | $151 | $6 |
| Ondansetron | 11 | $130 | $12 |
| Hydrocortisone | 19 | $127 | $7 |
| Omeprazole | 20 | $126 | $6 |
| Sulfamethoxazole-Trimethoprim | 28 | $115 | $4 |
| Gabapentin | 21 | $95 | $5 |
| Losartan | 13 | $88 | $7 |
| Amlodipine Besylate | 20 | $84 | $4 |
| Warfarin | 12 | $83 | $7 |
| Zolpidem | 13 | $81 | $6 |
2016: 48 drugs
| Revlimid | 38 | $326,940 | $8,604 |
| Gleevec | 39 | $289,813 | $7,431 |
| Imatinib Mesylate | 33 | $210,214 | $6,370 |
| Ibrance | 13 | $136,142 | $10,472 |
| Tarceva | 17 | $123,380 | $7,258 |
| Votrient | 15 | $111,907 | $7,460 |
| Neupogen | 49 | $88,329 | $1,803 |
| Procrit | 48 | $69,752 | $1,453 |
| Entecavir | 29 | $22,838 | $788 |
| Danazol | 67 | $22,018 | $329 |
| Raloxifene | 118 | $15,415 | $131 |
| Viread | 13 | $13,278 | $1,021 |
| Xarelto | 32 | $11,163 | $349 |
| Cyclosporine | 19 | $7,662 | $403 |
| Janumet | 12 | $4,497 | $375 |
| Tamoxifen Citrate | 174 | $3,881 | $22 |
| Anastrozole | 336 | $3,509 | $10 |
| Hydroxyurea | 172 | $3,483 | $20 |
| Pilocarpine | 16 | $1,583 | $99 |
| Allopurinol | 86 | $935 | $11 |
| Dexamethasone | 74 | $685 | $9 |
| Hydrocodone-Acetaminophen | 14 | $633 | $45 |
| Letrozole | 56 | $628 | $11 |
| Leucovorin | 21 | $614 | $29 |
| Levothyroxine | 26 | $550 | $21 |
| Ondansetron | 41 | $499 | $12 |
| Prednisone | 83 | $411 | $5 |
| Alendronate | 81 | $402 | $5 |
| Acyclovir | 39 | $371 | $10 |
| Atorvastatin | 16 | $370 | $23 |
| Paroxetine | 54 | $369 | $7 |
| Tramadol | 43 | $359 | $8 |
| Potassium Chloride | 12 | $302 | $25 |
| Ondansetron Odt | 18 | $295 | $16 |
| Warfarin | 15 | $257 | $17 |
| Omeprazole | 43 | $224 | $5 |
| Montelukast | 28 | $202 | $7 |
| Famotidine | 34 | $160 | $5 |
| Meloxicam | 36 | $134 | $4 |
| Hydrocortisone | 26 | $122 | $5 |
| Gabapentin | 25 | $90 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $89 | $7 |
| Carvedilol | 11 | $64 | $6 |
| Losartan | 12 | $63 | $5 |
| Lidocaine Hcl Viscous | 13 | $51 | $4 |
| Nystatin | 13 | $50 | $4 |
| Metformin | 11 | $45 | $4 |
| Amoxicillin | 12 | $19 | $2 |
2015: 42 drugs
| Gleevec | 47 | $343,590 | $7,310 |
| Revlimid | 28 | $224,568 | $8,020 |
| Nexavar | 13 | $161,258 | $12,404 |
| Procrit | 73 | $131,546 | $1,802 |
| Tarceva | 18 | $106,547 | $5,919 |
| Votrient | 14 | $96,862 | $6,919 |
| Stivarga | 12 | $77,381 | $6,448 |
| Neupogen | 38 | $65,023 | $1,711 |
| Entecavir | 31 | $28,892 | $932 |
| Baraclude | 22 | $27,559 | $1,253 |
| Danazol | 65 | $19,568 | $301 |
| Raloxifene | 113 | $17,564 | $155 |
| Viread | 13 | $12,412 | $955 |
| Cyclosporine | 20 | $7,846 | $392 |
| Hydroxyurea | 141 | $3,314 | $24 |
| Leukeran | 17 | $3,239 | $191 |
| Exemestane | 11 | $3,110 | $283 |
| Eliquis | 11 | $2,947 | $268 |
| Tamoxifen Citrate | 128 | $2,526 | $20 |
| Anastrozole | 225 | $2,402 | $11 |
| Pilocarpine | 17 | $1,393 | $82 |
| Allopurinol | 95 | $1,029 | $11 |
| Oxycodone-Acetaminophen | 22 | $860 | $39 |
| Bicalutamide | 31 | $827 | $27 |
| Levothyroxine | 41 | $583 | $14 |
| Levetiracetam | 12 | $511 | $43 |
| Ibandronate | 13 | $497 | $38 |
| Alendronate | 89 | $453 | $5 |
| Omeprazole | 39 | $436 | $11 |
| Prednisone | 74 | $394 | $5 |
| Letrozole | 35 | $382 | $11 |
| Dexamethasone | 42 | $339 | $8 |
| Atorvastatin | 11 | $336 | $31 |
| Tramadol | 39 | $305 | $8 |
| Acyclovir | 34 | $305 | $9 |
| Paroxetine | 23 | $174 | $8 |
| Ondansetron | 17 | $174 | $10 |
| Montelukast | 16 | $160 | $10 |
| Metformin | 13 | $119 | $9 |
| Insulin | 17 | $105 | $6 |
| Hydrocortisone | 16 | $101 | $6 |
| Famotidine | 15 | $71 | $5 |
2014: 45 drugs
| Tarceva | 38 | $207,116 | $5,450 |
| Gleevec | 37 | $195,071 | $5,272 |
| Procrit | 86 | $169,610 | $1,972 |
| Revlimid | 14 | $139,888 | $9,992 |
| Thalomid | 13 | $100,959 | $7,766 |
| Afinitor | 13 | $96,307 | $7,408 |
| Danazol | 87 | $21,481 | $247 |
| Baraclude | 11 | $12,326 | $1,121 |
| Evista | 51 | $12,200 | $239 |
| Raloxifene | 47 | $10,254 | $218 |
| Exemestane | 16 | $5,976 | $373 |
| Anastrozole | 179 | $4,420 | $25 |
| Doxycycline Hyclate | 14 | $3,440 | $246 |
| Hydroxyurea | 120 | $2,398 | $20 |
| Letrozole | 58 | $1,407 | $24 |
| Tamoxifen Citrate | 72 | $1,308 | $18 |
| Alendronate | 129 | $938 | $7 |
| Oxybutynin Chloride Er | 11 | $843 | $77 |
| Bicalutamide | 26 | $805 | $31 |
| Atorvastatin | 29 | $760 | $26 |
| Megestrol Acetate | 14 | $589 | $42 |
| Potassium Chloride | 25 | $578 | $23 |
| Omeprazole | 70 | $472 | $7 |
| Pilocarpine | 13 | $429 | $33 |
| Dexamethasone | 49 | $392 | $8 |
| Allopurinol | 57 | $387 | $7 |
| Tramadol | 42 | $384 | $9 |
| Pravastatin | 14 | $381 | $27 |
| Prednisone | 56 | $367 | $7 |
| Cilostazol | 13 | $312 | $24 |
| Levothyroxine | 18 | $299 | $17 |
| Paroxetine | 16 | $261 | $16 |
| Montelukast | 19 | $254 | $13 |
| Acyclovir | 29 | $207 | $7 |
| Metformin | 21 | $204 | $10 |
| Insulin | 16 | $203 | $13 |
| Ondansetron | 16 | $187 | $12 |
| Amlodipine Besylate | 28 | $160 | $6 |
| Hydrocortisone | 23 | $151 | $7 |
| Lisinopril-Hydrochlorothiazide | 13 | $114 | $9 |
| Famotidine | 16 | $102 | $6 |
| Meloxicam | 26 | $96 | $4 |
| Simvastatin | 11 | $96 | $9 |
| Sulfamethoxazole-Trimethoprim | 13 | $67 | $5 |
| Warfarin | 12 | $59 | $5 |
2013: 53 drugs
| Tarceva | 42 | $226,375 | $5,390 |
| Procrit | 131 | $161,026 | $1,229 |
| Gleevec | 21 | $132,927 | $6,330 |
| Revlimid | 16 | $130,131 | $8,133 |
| Xalkori | 13 | $70,250 | $5,404 |
| Neupogen | 28 | $49,404 | $1,764 |
| Nexavar | 11 | $39,442 | $3,586 |
| Evista | 108 | $25,510 | $236 |
| Danazol | 77 | $21,791 | $283 |
| Cyclophosphamide | 17 | $10,148 | $597 |
| Megace Es | 12 | $9,656 | $805 |
| Exemestane | 28 | $7,893 | $282 |
| Anastrozole | 255 | $7,622 | $30 |
| Uloric | 21 | $4,165 | $198 |
| Doxycycline Hyclate | 16 | $3,825 | $239 |
| Prandin | 11 | $3,764 | $342 |
| Bicalutamide | 34 | $2,402 | $71 |
| Letrozole | 80 | $2,106 | $26 |
| Atelvia | 14 | $1,939 | $139 |
| Megestrol Acetate | 33 | $1,921 | $58 |
| Hydroxyurea | 113 | $1,809 | $16 |
| Ibandronate | 16 | $1,608 | $101 |
| Alendronate | 164 | $1,510 | $9 |
| Clopidogrel | 21 | $925 | $44 |
| Potassium Chloride | 38 | $887 | $23 |
| Tamoxifen Citrate | 56 | $819 | $15 |
| Omeprazole | 85 | $711 | $8 |
| Atorvastatin | 27 | $646 | $24 |
| Tramadol | 49 | $553 | $11 |
| Pilocarpine | 15 | $545 | $36 |
| Anagrelide | 12 | $464 | $39 |
| Allopurinol | 55 | $385 | $7 |
| Lidocaine-Prilocaine | 14 | $371 | $26 |
| Ondansetron | 20 | $297 | $15 |
| Insulin | 15 | $288 | $19 |
| Amlodipine Besylate | 24 | $285 | $12 |
| Paroxetine | 25 | $283 | $11 |
| Cilostazol | 11 | $272 | $25 |
| Prednisone | 70 | $251 | $4 |
| Losartan | 11 | $240 | $22 |
| Acyclovir | 18 | $234 | $13 |
| Hydrocortisone | 27 | $222 | $8 |
| Levothyroxine | 23 | $215 | $9 |
| Prochlorperazine Maleate | 18 | $205 | $11 |
| Metformin | 14 | $156 | $11 |
| Meloxicam | 23 | $148 | $6 |
| Gabapentin | 12 | $146 | $12 |
| Azithromycin | 11 | $143 | $13 |
| Warfarin | 18 | $137 | $8 |
| Lisinopril-Hydrochlorothiazide | 16 | $126 | $8 |
| Simvastatin | 11 | $115 | $10 |
| Sulfamethoxazole-Trimethoprim | 22 | $89 | $4 |
| Dexamethasone | 14 | $84 | $6 |
Money from drug and device companies
$3,817 in 2025
| 2025 | 36 | 140 | None | $3,817 |
| 2024 | 32 | 115 | None | $2,858 |
| 2023 | 27 | 85 | None | $2,325 |
| 2022 | 26 | 105 | None | $2,332 |
| 2021 | 25 | 64 | None | $1,696 |
| 2020 | 17 | 41 | $1,200 | $2,041 |
| 2019 | 23 | 90 | $4,120 | $6,032 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $607 | 19 payments
|
| Janssen Biotech | Rybrevant | $389 | 12 payments
|
| Merck Sharp & Dohme | Keytruda | $277 | 10 payments
|
| Novartis Pharmaceuticals | Kisqali | $254 | 10 payments
|
| BeOne Medicines USA | Tevimbra | $223 | 5 payments
|
| GlaxoSmithKline | Jemperli | $197 | 9 payments
|
See all 132 published payments
| Acrotech Biopharma | Meals · 2025-12-13 | None | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-11 | Opdivo | $16 |
| Novartis Pharmaceuticals | Meals · 2025-12-10 | Pluvicto | $27 |
| Novocure | Meals · 2025-12-10 | Optune Lua (Novottf-200t) | $46 |
| BeOne Medicines USA | Meals · 2025-12-08 | Brukinsa | $34 |
| Merck Sharp & Dohme | Meals · 2025-12-04 | Keytruda | $34 |
| BeOne Medicines USA | Meals · 2025-12-03 | Tevimbra | $32 |
| Kite Pharma | Meals · 2025-12-03 | Yescarta | $24 |
| Abbvie | Meals · 2025-12-02 | Imbruvica | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-25 | Enhertu | $31 |
| PharmaEssentia USA | Meals · 2025-11-03 | Besremi | $27 |
| Coherus Oncology | Meals · 2025-10-30 | Loqtorzi | $25 |
| Astellas Pharma US | Meals · 2025-10-27 | Xtandi | $32 |
| Aveo Pharmaceuticals | Meals · 2025-10-23 | Fotivda | $27 |
| Novartis Pharmaceuticals | Meals · 2025-10-22 | Kisqali | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-21 | None | $32 |
| Novo Nordisk | Meals · 2025-10-20 | Wegovy | $25 |
| Pfizer | Meals · 2025-10-20 | Ibrance | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-16 | Imfinzi | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-16 | Nubeqa | $24 |
| Novocure | Meals · 2025-10-14 | Optune Lua (Novottf-200t) | $17 |
| Merck Sharp & Dohme | Meals · 2025-10-02 | Keytruda | $22 |
| GlaxoSmithKline | Meals · 2025-10-01 | Ojjaara | $22 |
| Amgen | Meals · 2025-09-30 | Kyprolis | $27 |
| Merck Sharp & Dohme | Meals · 2025-09-25 | Keytruda | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-24 | Enhertu | $32 |
| Agios Pharmaceuticals | Meals · 2025-09-22 | Pyrukynd | $36 |
| Eisai | Meals · 2025-09-17 | Lenvima | $19 |
| Janssen Biotech | Meals · 2025-09-15 | Erleada | $24 |
| Janssen Biotech | Meals · 2025-09-15 | Erleada | $4 |
| Merck Sharp & Dohme | Meals · 2025-09-11 | Keytruda | $23 |
| GlaxoSmithKline | Meals · 2025-09-10 | Ojjaara | $20 |
| Rigel Pharmaceuticals | Meals · 2025-09-08 | Tavalisse | $27 |
| Janssen Biotech | Education · 2025-09-05 | Erleada | $85 |
| GlaxoSmithKline | Meals · 2025-09-05 | Jemperli | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-04 | Opdivo | $26 |
| Progenics Pharmaceuticals | Meals · 2025-09-03 | Pylarify | $26 |
| Merck Sharp & Dohme | Meals · 2025-08-28 | Keytruda | $27 |
| Novartis Pharmaceuticals | Meals · 2025-08-27 | Pluvicto | $17 |
| Novartis Pharmaceuticals | Meals · 2025-08-27 | Pluvicto | $8 |
| Janssen Biotech | Meals · 2025-08-25 | Rybrevant | $38 |
| Janssen Biotech | Meals · 2025-08-21 | Darzalex | $31 |
| Janssen Biotech | Meals · 2025-08-21 | Darzalex | $6 |
| Pfizer | Meals · 2025-08-13 | Xtandi | $35 |
| Eisai | Meals · 2025-08-13 | Lenvima | $21 |
| Genzyme | Meals · 2025-08-11 | Ayvakit | $30 |
| Kite Pharma | Meals · 2025-08-07 | Yescarta | $28 |
| Eisai | Meals · 2025-08-01 | Lenvima | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-30 | Opdivo | $21 |
| Legend Biotech USA | Education · 2025-07-26 | Carvykti | $16 |
| Astellas Pharma US | Meals · 2025-07-24 | Xtandi | $27 |
| Daiichi Sankyo | Meals · 2025-07-23 | Enhertu | $29 |
| Daiichi Sankyo | Meals · 2025-07-15 | Datroway | $30 |
| Pfizer | Education · 2025-07-14 | Ibrance | $31 |
| Puma Biotechnology | Meals · 2025-07-09 | Nerlynx | $29 |
| Novartis Pharmaceuticals | Meals · 2025-07-02 | Kisqali | $36 |
| Gilead Sciences | Meals · 2025-06-25 | Trodelvy | $20 |
| BeOne Medicines USA | Meals · 2025-06-16 | Tevimbra | $29 |
| Eisai | Meals · 2025-06-16 | Lenvima | $28 |
| Merck Sharp & Dohme | Meals · 2025-06-12 | Keytruda | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-09 | Enhertu | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-09 | Enhertu | $17 |
| Array Biopharma | Meals · 2025-06-05 | Xalkori | $25 |
| GlaxoSmithKline | Meals · 2025-06-03 | Jemperli | $19 |
| Merck Sharp & Dohme | Meals · 2025-05-29 | Keytruda | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-28 | Calquence | $21 |
| Novocure | Meals · 2025-05-27 | Optune Lua (Novottf-200t) | $23 |
| GlaxoSmithKline | Meals · 2025-05-22 | Ojjaara | $27 |
| Abbvie | Meals · 2025-05-21 | Elahere | $31 |
| Daiichi Sankyo | Meals · 2025-05-15 | Enhertu | $14 |
| Lilly USA | Meals · 2025-05-14 | Jaypirca | $31 |
| Rigel Pharmaceuticals | Meals · 2025-05-13 | Tavalisse | $34 |
| Janssen Biotech | Meals · 2025-05-12 | Rybrevant | $38 |
| BeOne Medicines USA | Meals · 2025-05-09 | Tevimbra | $10 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-05-08 | None | $100 |
| Merck Sharp & Dohme | Meals · 2025-05-08 | Keytruda | $25 |
| Progenics Pharmaceuticals | Meals · 2025-05-07 | Pylarify | $26 |
| PharmaEssentia USA | Meals · 2025-05-06 | Besremi | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-05 | Calquence | $26 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Pluvicto | $28 |
| Astellas Pharma US | Meals · 2025-04-30 | Vyloy | $20 |
| Sobi | Meals · 2025-04-29 | Vonjo | $37 |
| Sobi | Education · 2025-04-29 | None | $94 |
| GlaxoSmithKline | Meals · 2025-04-24 | Jemperli | $23 |
| BeOne Medicines USA | Meals · 2025-04-24 | Tevimbra | $118 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-24 | Advate | $23 |
| Abbvie | Meals · 2025-04-22 | Imbruvica | $21 |
| Deciphera Pharmaceuticals | Meals · 2025-04-22 | Qinlock | $34 |
| Legend Biotech USA | Meals · 2025-04-21 | Carvykti | $30 |
| Janssen Biotech | Meals · 2025-04-17 | Rybrevant | $4 |
| Janssen Biotech | Meals · 2025-04-17 | Rybrevant | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-16 | Imfinzi | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-14 | Eliquis | $26 |
| Merck Sharp & Dohme | Meals · 2025-04-10 | Keytruda | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-09 | Enhertu | $35 |
| Aveo Pharmaceuticals | Meals · 2025-04-08 | Fotivda | $29 |
| Aveo Pharmaceuticals | Education · 2025-04-08 | Fotivda | $20 |
| Novartis Pharmaceuticals | Meals · 2025-04-07 | Pluvicto | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-07 | Tagrisso | $29 |
| GlaxoSmithKline | Meals · 2025-03-24 | Jemperli | $28 |
| Eisai | Meals · 2025-03-19 | Lenvima | $21 |
| PharmaEssentia USA | Meals · 2025-03-19 | Besremi | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-13 | Nubeqa | $28 |
| Astellas Pharma US | Meals · 2025-03-12 | Xtandi | $25 |
| Legend Biotech USA | Meals · 2025-03-10 | Carvykti | $29 |
| Abbvie | Meals · 2025-03-06 | Elahere | $25 |
| Novartis Pharmaceuticals | Meals · 2025-03-05 | Pluvicto | $30 |
| Celgene | Meals · 2025-03-04 | Reblozyl | $25 |
| GlaxoSmithKline | Meals · 2025-03-04 | Jemperli | $16 |
| Astellas Pharma US | Meals · 2025-03-03 | Xtandi | $28 |
| Blueprint Medicines | Meals · 2025-02-27 | Ayvakit | $29 |
| Janssen Biotech | Meals · 2025-02-25 | Darzalex | $44 |
| Novocure | Meals · 2025-02-24 | Optune Lua (Novottf-200t) | $30 |
| Novartis Pharmaceuticals | Meals · 2025-02-20 | Kisqali | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-13 | Imfinzi | $29 |
| Novartis Pharmaceuticals | Meals · 2025-02-11 | Kisqali | $34 |
| Progenics Pharmaceuticals | Meals · 2025-02-06 | Pylarify | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-04 | Calquence | $30 |
| Janssen Biotech | Meals · 2025-02-03 | Rybrevant | $37 |
| Stemline Therapeutics | Meals · 2025-01-30 | Orserdu | $30 |
| Aveo Pharmaceuticals | Meals · 2025-01-28 | Fotivda | $29 |
| Coherus Oncology | Meals · 2025-01-27 | Loqtorzi | $39 |
| Merck Sharp & Dohme | Meals · 2025-01-23 | Keytruda | $28 |
| Rigel Pharmaceuticals | Meals · 2025-01-20 | Tavalisse | $39 |
| GlaxoSmithKline | Meals · 2025-01-17 | Jemperli | $17 |
| Janssen Biotech | Meals · 2025-01-16 | Darzalex | $41 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-16 | Enhertu | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Tagrisso | $38 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-10 | Lynparza | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-09 | Imfinzi | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-09 | Imfinzi | $43 |
| Celgene | Meals · 2025-01-06 | Reblozyl | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,858
| AstraZeneca Pharmaceuticals LP | Lynparza | $552 | 17 payments
|
| Astellas Pharma US | Vyloy | $262 | 7 payments
|
| Novartis Pharmaceuticals | Scemblix | $230 | 8 payments
|
| Janssen Biotech | Darzalex | $207 | 6 payments
|
| Pfizer | Ibrance | $197 | 15 payments
|
| Coherus Biosciences | Udenyca | $147 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $113 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $97 | 3 payments
|
| Abbvie | Imbruvica | $96 | 4 payments
|
| Array Biopharma | Xalkori | $74 | 3 payments
|
| GlaxoSmithKline | Ojjaara | $73 | 3 payments
|
| Sobi | Vonjo | $67 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $66 | 3 payments
|
| Celgene | Reblozyl | $61 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $59 | 2 payments
|
| PharmaEssentia USA | Besremi | $56 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $53 | 2 payments
|
| Daiichi Sankyo | Enhertu | $48 | 2 payments
|
| Taiho Oncology | Lonsurf | $36 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $36 | 1 payment
|
| EMD Serono | None | $34 | 1 payment
|
| Stemline Therapeutics | Orserdu | $34 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $34 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $33 | 1 payment
|
| Lilly USA | Verzenio | $30 | 1 payment
|
| Genmab U.S. | Epkinly | $28 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Tempus AI | None | $25 | 1 payment
|
| BeiGene USA | Tevimbra | $23 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $22 | 1 payment
|
| Gilead Sciences | None | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $20 | 1 payment
|
2023: $2,325
| AstraZeneca Pharmaceuticals LP | Tagrisso | $344 | 10 payments
|
| Seagen | Adcetris | $254 | 6 payments
|
| Astellas Pharma US | Padcev | $230 | 4 payments
|
| Janssen Biotech | Imbruvica | $188 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $173 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $146 | 14 payments
|
| Lilly USA | Verzenio | $132 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $96 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $95 | 1 payment
|
| Daiichi Sankyo | Enhertu | $89 | 4 payments
|
| Progenics Pharmaceuticals | Pylarify | $67 | 3 payments
|
| EMD Serono | Bavencio | $50 | 2 payments
|
| Genentech USA | Perjeta | $50 | 2 payments
|
| Pfizer | Ibrance | $45 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $45 | 2 payments
|
| Celgene | Reblozyl | $40 | 2 payments
|
| Novartis Pharmaceuticals | Pluvicto | $34 | 1 payment
|
| Elekta | Elekta Unity | $34 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $31 | 1 payment
|
| Amgen | Nplate | $27 | 1 payment
|
| CTI BioPharma | Vonjo | $27 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $26 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $24 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Abbvie | Venclexta | $21 | 1 payment
|
| Kite Pharma | None | $20 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $16 | 1 payment
|
2022: $2,332
| AstraZeneca Pharmaceuticals LP | Enhertu | $346 | 12 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $276 | 15 payments
|
| Janssen Biotech | Imbruvica | $264 | 8 payments
|
| Seagen | Adcetris | $203 | 7 payments
|
| Lilly USA | Verzenio | $154 | 6 payments
|
| Rigel Pharmaceuticals | Tavalisse | $149 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $100 | 5 payments
|
| GlaxoSmithKline | Blenrep | $95 | 4 payments
|
| Celgene | Reblozyl | $92 | 4 payments
|
| Amgen | Lumakras | $86 | 3 payments
|
| Pfizer | Xalkori | $76 | 3 payments
|
| Kite Pharma | None | $59 | 2 payments
|
| Sobi | Doptelet | $54 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $46 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $46 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $41 | 2 payments
|
| ADC Therapeutics America | None | $39 | 1 payment
|
| Puma Biotechnology | Nerlynx | $28 | 1 payment
|
| Incyte | Monjuvi | $26 | 1 payment
|
| Blueprint Medicines | Ayvakit | $26 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Genentech USA | None | $24 | 1 payment
|
| Clovis Oncology | Rubraca | $22 | 1 payment
|
| MorphoSys US | Monjuvi | $21 | 1 payment
|
| Astellas Pharma US | Padcev | $17 | 1 payment
|
| Gilead Sciences | Trodelvy | $16 | 1 payment
|
2021: $1,696
| E.R. Squibb & Sons L.L.C. | None | $204 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $193 | 5 payments
|
| Lilly USA | Cyramza | $178 | 4 payments
|
| Janssen Biotech | Erleada | $170 | 5 payments
|
| Astellas Pharma US | Padcev | $123 | 6 payments
|
| Novartis Pharmaceuticals | Lutathera | $101 | 5 payments
|
| Pfizer | Ibrance | $100 | 4 payments
|
| Seagen | Adcetris | $92 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $65 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $44 | 2 payments
|
| Array Biopharma | Braftovi | $43 | 2 payments
|
| TOLMAR Pharmaceuticals | Fensolvi | $42 | 1 payment
|
| Eisai | Lenvima | $41 | 2 payments
|
| Incyte | Monjuvi | $40 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $32 | 1 payment
|
| Blueprint Medicines | Gavreto | $32 | 1 payment
|
| Amgen | Nplate | $30 | 1 payment
|
| GlaxoSmithKline | Blenrep | $27 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $26 | 1 payment
|
| Puma Biotechnology | Nerlynx | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $24 | 1 payment
|
| Clovis Oncology | Rubraca | $19 | 1 payment
|
| Celgene | Inrebic | $16 | 1 payment
|
| Foundation Medicine | Foundationone | $15 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
2020: $2,041
| Rigel Pharmaceuticals | Tavalisse | $1,200 | 1 payment
|
| Pfizer | Ibrance | $292 | 13 payments
|
| Dova Pharmaceuticals | Doptelet | $87 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | None | $71 | 4 payments
|
| GlaxoSmithKline | Blenrep | $68 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $54 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $38 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $36 | 2 payments
|
| Seagen | Padcev | $31 | 2 payments
|
| Janssen Biotech | Darzalex | $30 | 1 payment
|
| Genzyme | Sarclisa | $24 | 1 payment
|
| Kite Pharma | Yescarta | $23 | 1 payment
|
| Astellas Pharma US | Padcev | $21 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $19 | 1 payment
|
| Lilly USA | Cyramza | $18 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $15 | 1 payment
|
| Array Biopharma | Braftovi | $15 | 1 payment
|
2019: $6,032
| AstraZeneca Pharmaceuticals LP | Imfinzi | $4,459 | 10 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $244 | 17 payments
|
| Novartis Pharmaceuticals | Promacta | $205 | 10 payments
|
| Pfizer | Ibrance | $204 | 19 payments
|
| Alexion Pharmaceuticals | None | $125 | 1 payment
|
| Amarin Pharma | Vascepa | $100 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $91 | 5 payments
|
| Foundation Medicine | Foundationone | $75 | 2 payments
|
| Lilly USA | Verzenio | $73 | 4 payments
|
| Janssen Biotech | Darzalex | $63 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $58 | 3 payments
|
| Merz North America | Xeomin | $52 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $49 | 2 payments
|
| Celgene | Abraxane | $41 | 2 payments
|
| Jazz Pharmaceuticals | Sunosi | $38 | 2 payments
|
| Clovis Oncology | Rubraca | $26 | 2 payments
|
| EMD Serono | Bavencio | $25 | 1 payment
|
| Seattle Genetics | Adcetris | $22 | 1 payment
|
| Array BioPharma | Braftovi | $22 | 1 payment
|
| Puma Biotechnology | Nerlynx | $17 | 1 payment
|
| Vyera Pharmaceuticals | Daraprim 30 Tablet in 1 Bottle | $16 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $15 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
Professional record
- NPI
- 1053317818
- Licence
- CA G44983California G44983: Current · expires 2027-01-31
- Trained
- University of California, San Francisco School of Medicine, 1980
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 200 Jose Figueres Ave, Ste 245, San Jose, CA, 95116
- NPI first listed
- 2005-06-24
- NPI last updated
- 2008-05-13
This is when the NPI record was last certified, not a medical board exam.